NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced today the continued expansion of the Company’s leadership team with the appo…
Author: Business Wire
Warby Parker Releases Financial Guidance for the Third Quarter and Fiscal Year 2021 and Fiscal Year 2022
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (the “Company”), a founder-led direct-to-consumer eyewear brand, today issued guidance for the third quarter ending September 30, 2021 and for the fiscal years ending December 31, 2021 and 2022. “As we look …
US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina and Florida
SARASOTA, Fla.–(BUSINESS WIRE)– #Eyecare–US Eye, a physician-led network of patient-centric eye care practices, has expanded its practice base to 50 clinics and five surgery centers.
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicen…
Global Synoptophore Markets 2021-2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Synoptophore Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering. The synoptophore market is projected to register a CAGR of around 4% during th…
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that …
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Global Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report 2021-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Treatment Devices Market 2021-2028” report has been added to ResearchAndMarkets.com’s offering. The global dry eye treatment devices market size is estimated to reach USD 414.2 million by 2028. It is anticip…
Optic Neuritis (Ophthalmology) Drugs Pipeline Guide 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optic Neuritis (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive information on the therapeutics under development for Optic Neurit…
Global Eye Care Surgical Devices Market 2021-2025: High Incidence of Eye Diseases and growing Number of MI Glaucoma Surgeries Driving Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eye Care Surgical Devices Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering. The eye care surgical devices market is poised to grow by $ 3.49 bn during 2021-2025, progressing at a CAGR of …
Griffey Eye Care, Center for Visual Surgical Excellence Join US Eye
CHESAPEAKE, Va.–(BUSINESS WIRE)– #Eyecare–Griffey Eye Care and the Center for Visual Surgical Excellence have joined the US Eye network of premium eye care practices.
US Eye Practice Network Expands into North Carolina
ELIZABETH CITY, N.C.–(BUSINESS WIRE)–US Eye has expanded into North Carolina with the addition of Albemarle Eye Center and Precision Eye Care to its network.
Global Dry Age-Related Macular Degeneration Market and Competitive Landscape 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Age-Related Macular Degeneration Market and Competitive Landscape – 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Dry Age-Related Macular Degen…
Sungate Cataract, LASIK and Vision Center Joins US Eye Network
HILTON HEAD, S.C.–(BUSINESS WIRE)–Sungate Cataract, LASIK and Vision Center, one of the Lowcountry’s leading multi-specialty ophthalmology groups, has partnered with US Eye.
Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer
PHILADELPHIA–(BUSINESS WIRE)– #biotechnology–Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the appointment of Mahen Gundecha as …
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Edgemont Partners Advises Tennessee Retina on its Sale to Retina Consultants of America
NEW YORK–(BUSINESS WIRE)–Edgemont Partners acted as exclusive financial advisor to Tennessee Retina on its Sale to Retina Consultants of America.
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported up…
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that …
GenSight Biologics annonce les conclusions positives du Data Safety Monitoring Board (DSMB) de l’étude clinique de Phase I/II PIONEER de GS030 comme traitement optogénétique de la rétinopathie pigmentaire
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME), une société biopharmaceutique dédiée au développement et à la commercialisation des thérapies géniques innovantes pour le traitement de…